- Patients
- Clinical Research
- Clinical trials
- Seagen RC48-G001
2024-06-20T09:33:05.499Z
Seagen RC48-G001
Seagen RC48-G001
Urothelial cancer
A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Urothelial cancer
Study Phase
II
Trial registration
Number: NCT04879329
GenesisCare Location(s)
GenesisCare North Shore
GenesisCare North Shore
:::
Principal Investigator(s)